Walmart, Costco, Amazon expected to dominate direct-to-consumer GLP-1 drugs

As employers increasingly scale back insurance coverage for popular GLP-1 weight-loss medications like Wegovy and Zepbound, a growing number of patients are turning to direct-to-consumer options. Because these drugs often lack insurance backing when prescribed for weight management, the search for competitive pricing is driving a major shift in the retail pharmacy landscape.

Retail Giants Set to Capture Market Share

According to an article by CNBC, industry titans such as Walmart, Costco, CVS, and Amazon are positioned to dominate this evolving direct-to-consumer market. Current providers like Noom and Ro are setting the stage with monthly costs ranging from $299 to $499, depending on the specific dosage required.

The Long-Term Retail Play

The business strategy behind these retailers is about more than just a single monthly prescription. Because patients often remain on GLP-1 drugs for years or even decades to maintain their results, retailers are banking on long-term customer loyalty.

"Retailers are betting that if they can become the front door for obesity care, they’ll earn a relationship that extends far beyond a single GLP-1 prescription," Eric Bormel, managing director specializing in digital healthcare at Solomon Partners’ healthcare group, explained to CNBC.

Expanding the Consumer Basket

By capturing the "front door" of obesity treatment, these retail chains anticipate that patients will consolidate their healthcare and retail spending under one roof. Whether it is moving other prescriptions to a Walmart or Costco pharmacy or purchasing new clothing as a result of weight loss, these networks are betting that the GLP-1 boom will pay dividends across their entire business ecosystem, even if the individual drug margins remain low.